id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6002-0007,FDA,FDA-2017-E-6002,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,,2019-09-17T13:26:50Z,,0,0,0900006483f86b46
FDA-2017-E-6002-0006,FDA,FDA-2017-E-6002,"Determination of Regulatory Review Period for Purposes of Patent
Extension; RUBRACA",Notice,Determinations,2018-12-28T05:00:00Z,2018,12,2018-12-28T05:00:00Z,2019-02-27T04:59:59Z,2018-12-31T21:05:16Z,2018-28217,0,0,09000064839cbe97
FDA-2017-E-6002-0005,FDA,FDA-2017-E-6002,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T17:11:04Z,,0,0,09000064839c0235
FDA-2017-E-6002-0004,FDA,FDA-2017-E-6002,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T13:45:24Z,,0,0,090000648378b5ab
FDA-2017-E-6002-0003,FDA,FDA-2017-E-6002,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-10-17T04:00:00Z,2017,10,2017-10-17T04:00:00Z,,2017-10-17T19:48:29Z,,0,0,0900006482bd6061
FDA-2017-E-6002-0002,FDA,FDA-2017-E-6002,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2017-10-03T04:00:00Z,2017,10,2017-10-03T04:00:00Z,,2017-10-03T14:02:23Z,,0,0,0900006482b94322
FDA-2017-E-6002-0001,FDA,FDA-2017-E-6002,"Patent Extension Application from Swanson & Bratschun LLC (on behalf of Agouron Pharmaceuticals, LLC)",Other,Application,2017-10-03T04:00:00Z,2017,10,2017-10-03T04:00:00Z,,2017-10-03T13:51:14Z,,0,0,0900006482b940d5